Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At around 50c Float ~70M with NGIO going on the Nasdaq and the A37 with Merck besides the Covid-19 possibilities. Other subs look like a turnaround also.
Other Mods please step down for Sticky Purposes. Would like to sticky 11962. Each mod can sticky only 1 post.
New Team Member New Direction: Les Paull, Phd., CEO of QMVT LLC, which is responsible for sales and marketing of QMC’s innovations, states “The world must have a system that eliminates the fears and anxiety of not knowing who is able to return to work."
Cission and the Carlyl Group Investors. Patience looks like it will pay in spite of the current CE lol.
The beta test version is out and underway and certainly can be tweeked!
1)2M is 2M slows the rate of dilution.
2)The lawsuits from the predatory lender and other factors put QMC on the Pink.
3)Why would Williams and Hartigan join a sinking ship
4)India
Disagree, smart move considering the times.
Shareholder Update: LOI signed for $2M equity investment and JV to form Quantum Materials Vertical Technologies, LLC.
http://www.globenewswire.com/news-release/2020/01/27/1975512/0/en/Quantum-Materials-Corp-Provides-Investor-Update-on-Operations.html
Top of the board all
Nice Post
Additionally, Les Paull, Phd., CEO of QMVT LLC, which is responsible for sales and marketing of QMC’s innovations, states “The world must have a system that eliminates the fears and anxiety of not knowing who is able to return to work."
http://www.globenewswire.com/news-release/2020/04/13/2015078/0/en/Quantum-Materials-Announces-QDX-HealthID-to-Support-Back-to-Work-Immunization-Passport-Programs.html
An Opinion Only. Have a nice weekend.
Generex Biotechnology Provides Update on the Development of an Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
Working with a team of corporate collaborators, academic advisors, and contract manufacturers to prepare contract proposals and bids for U.S. and international government health agencies to develop Ii-Key-SARS-CoV-2 peptide vaccines against COVID-19 for clinical testing and approval
http://www.globenewswire.com/news-release/2020/04/14/2015691/0/en/Generex-Biotechnology-Provides-Update-on-the-Development-of-an-Ii-Key-SARS-CoV-2-Peptide-Vaccine-Against-the-COVID-19-Pandemic.html
In the I-Box
Undervalued with NGIO NASDAQ Listing upcoming
I-Box Updates are up
B A M you are correct, Latest adventure into Covid-19 tracking leads me to believe QMC is on to something. Certainly getting recognition by Atlantic Council and GBBC.
Separate webinars Thursday and Monday
with Quantum Materials Corp CTO Jay Williams speaking at each!
Monday's is hosted by the Atlantic Council
When: Monday, 20 April 12:30-1:30pm EDT
Where: Hosted on the the Atlantic Council website
What: A virtual roundtable discussion on “Strategic standards now, so people can return to work soon” – Presented by the Atlantic Council GeoTech Center.
Across the globe, momentum is building to get people back to work and open businesses. As we contemplate a return to the workplace it is critical to define strategic standards and identify key issues for a safe pathway back to the workplace. Until a vaccine is found most experts envision a solution based on interdisciplinary and societal-wide collaboration. Many policies under discussion include an array of elements — innovative combinations of diagnostic tests for antibodies or a record of treatment and recovery from COVID–19, digital technologies, transitional workplace arrangements, blended work settings, and supportive public policies.
On Monday, April 20th at 12:30pm EDT, the Atlantic Council will convene an expert panel to explore the strategic standards required to properly identify, authenticate, and certify a workforce ready for work in a post-corona virus workplace. Hear from leading experts at the intersection of COVID–19, health science, digital technologies, workplace law and data privacy to understand what your agency, company, or institution can do to rapidly get your team back to work. Join the Atlantic Council’s GeoTech Center for a candid, incisive and insightful discussion designed inform your personal and professional decisions with the latest strategic information and experience from the field.
The Atlantic Council GeoTech Center encourages global tech collaborations, evaluates good tech choices as well as measurable policy alternatives, and educates world leaders and the public on issues related to global tech competition.
Took a bite of the .0054 yummy.
Fingers crossed. Got hungry and bought a few JACK while waiting. lol
Update in the Race for a Vaccine WHO Listed
MIRAMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company is working with corporate collaborators, academic advisors, and contract manufacturers, with guidance from BARDA and other government agencies to develop a plan and budget for testing a synthetic peptide vaccine against the coronavirus SARS-CoV-2 using the company’s proprietary and patented Ii-Key immune system activation technology. Because Generex’ subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express) has a long history of developing the Ii-Key peptide vaccine technology with the goal of rapidly responding to potential pandemic threats, we have been able to rapidly mobilize our efforts so as to be prepared to respond to the COVID-19 global pandemic. By working towards partnerships and contracts with government and private collaborators, our goal is to accelerate the discovery and development of a safe and effective vaccine to help fight COVID-19.
Collaborating with government and academia
Generex is collaborating with private collaborators and academic experts to evaluate a number of peptide vaccine candidates for future clinical use. Our research partners have identified amino acid sequences that are predicted via computational algorithms to be antigenic epitopes of the SARS-CoV-2 coronavirus, and we are linking these epitopes with Ii-Key to develop a synthetic peptide vaccine.
Generex is also in discussion with U.S. and international governments to support clinical development and manufacturing capabilities for a vaccine. The company has agreed to terms with a peptide manufacturer to produce research grade peptides that will be used to screen against blood samples from patients who have recovered from COVID-19. Generex is in discussions with major contract companies to plan for the manufacturing of GMP grade clinical peptides to support the company’s planned safety and immunogenicity clinical trial, which is projected to initiate vaccinations in mid-summer.
Due to the ongoing pandemic emergency, the company is in discussions with these commercial contract manufacturers and the U.S. government to plan for the production of large-scale commercial batches of vaccine if the clinical trials are successful to support mass vaccination under a proposed emergency use authorization (EUA), as well as Phase III efficacy protocols starting in the Fall.
Researching vaccines for COVID-19
There are currently no specific treatments nor vaccines for COVID-19. Researchers across the world, including Generex, are investigating new products for the treatment and prevention of COVID-19, including the development of numerous vaccine modalities. A vaccine is a prophylaxis, or preventative, approach against disease. Through immunization, vaccines can activate a healthy immune system to produce an immune response that may provide long-term protection against viruses and bacterial pathogens. Although neutralizing antibodies are the principal defense against viral infection, two additional cell types are essential both for a robust defense and for immunological memory against subsequent infections. Cytotoxic T cells (CD8 cells) can kill the primary infected cells, the factories for virus production and release, and helper T cells (CD4 or Th cells) enhance production of both antibodies and the cytotoxic T cells and can afford immune memory for decades.
The Ii-Key technology that Generex has developed for over 15 years with tens of millions of dollars in research and development expenditures is designed to activate both the cellular (T cell) and humoral (antibody) immune response to create a “Complete Vaccine”. Generex is in discussions to develop a proprietary, patented Ii-Key-SARS-CoV-2 vaccine against the coronavirus and plans to work with the government and commercial collaborators to evaluate if vaccination with the peptide vaccine can immunize the population and protect against COVID-19. Our new, COVID-19 specific patents are currently being filed by our partner as provisional applications, and full applications will be filed in the U.S. and internationally on a country by country basis to protect the SARS-CoV-2 peptide epitopes as well as the Ii-Key-SARS-CoV-2 vaccines as additional in silico, in vitro, and in vivo data are compiled to support current and future claims. Generex has signed a licensing agreement that includes exclusivity to utilize the patented epitope sequences for Ii-Key peptide vaccines.
Generex President & CEO Joseph Moscato said, “My team and I are in discussions with the U.S. government about funding our vaccine development program, and we are speaking with people at Health Canada this week to discuss the Canadian regulatory path for approval in Canada. Our current plan is to conduct a clinical trial of our Ii-Key multivalent peptide vaccine to evaluate safety and immunogenicity as defined by activation of the cellular and humoral response. The 3-arm study design will compare the Ii-Key-SARS-CoV-2 vaccine alone and with immune adjuvant versus adjuvant alone. In the first stage of this immunogenicity trial, 20 healthy subjects will be enrolled in each arm, and will be vaccinated at day 0, given a booster vaccination on day 21, and have blood drawn for evaluation of immune response on day 31. A data safety monitoring board will review the interim results for safety and immune response before providing a go/no go decision to complete enrollment in the extension stage of the trial, which will enroll a total of an estimated 120 subjects. If approved by the FDA, this protocol will establish the data foundation for a large scale, mass vaccination protocol under an EUA.
To meet the potential demand for hundreds of millions of vaccine doses, we are in discussions with our GMP manufacturing contractors to start production of clinical/commercial supply as soon as the DSMB review is complete and satisfactory. Last week we submitted and presented our overall plan to the U.S. Corona Watch task force, and this week we will be detailing our plan in an application to BARDA. We are working diligently to achieve success by working to secure funding of the next stages of the COVID-19 vaccine development and clinical trials with the goal of having our vaccine ready for a mass vaccination by autumn if everything goes perfectly. If the clinical trials are successful, we then plan to partner with larger companies, such as retail pharmacy chains, to work towards vaccinating a large number of American and Canadian citizens to potentially protect the population against COVID-19.”
Mr. Moscato continued, “We have recruited the best of the best for our advisory panel and have identified clinical trial partners, contract manufacturers, regulatory consultants, and leading institutions, that if funding is secured and early test results are positive, will manufacture and conduct the clinical testing of our vaccine with world class leaders in virology and vaccinology. We have compiled a multidisciplinary team to prepare the BARDA proposal in the next week to 10 days. We are in discussions to secure immediate funding to support the BARDA application process and initial vaccine development work. From our knowledge, the U.S. government has nothing like the Generex COVID 19 Complete Vaccine technology in their pandemic preparedness portfolio, and while there are no guarantees that BARDA will approve our vaccine development proposal, the Ii-Key-SARS-CoV-2 vaccine is designed to be the only vaccine that specifically activates both the cellular and humoral immune response to provide long-lasting protection from COVID-19, so we are confident in our approach and position.”
Mr. Moscato concluded, “We have spoken with health authorities and officials from several other countries to discuss our vaccine development program in order to define the regulatory path and requirements for each specific country. We recognize that it is important that each participating country establish the regulatory guidelines, manufacturing processes, and clinical systems to manage vaccination of their populations. If the clinical trials are successful we will also work with local regulators on clinical trials, manufacturing, and distribution strategy for immunizing their populations."
To meet the potential demand for hundreds of millions of vaccine doses, we are in discussions with our GMP manufacturing contractors to start production of clinical/commercial supply as soon as the DSMB review is complete and satisfactory. Last week we submitted and presented our overall plan to the U.S. Corona Watch task force, and this week we will be detailing our plan in an application to BARDA. We are working diligently to achieve success by working to secure funding of the next stages of the COVID-19 vaccine development and clinical trials with the goal of having our vaccine ready for a mass vaccination by autumn if everything goes perfectly. If the clinical trials are successful, we then plan to partner with larger companies, such as retail pharmacy chains, to work towards vaccinating a large number of American and Canadian citizens to potentially protect the population against COVID-19.”
Generex President & CEO Joseph Moscato said, “My team and I are in discussions with the U.S. government about funding our vaccine development program, and we are speaking with people at Health Canada this week to discuss the Canadian regulatory path for approval in Canada. Our current plan is to conduct a clinical trial of our Ii-Key multivalent peptide vaccine to evaluate safety and immunogenicity as defined by activation of the cellular and humoral response. The 3-arm study design will compare the Ii-Key-SARS-CoV-2 vaccine alone and with immune adjuvant versus adjuvant alone. In the first stage of this immunogenicity trial, 20 healthy subjects will be enrolled in each arm, and will be vaccinated at day 0, given a booster vaccination on day 21, and have blood drawn for evaluation of immune response on day 31. A data safety monitoring board will review the interim results for safety and immune response before providing a go/no go decision to complete enrollment in the extension stage of the trial, which will enroll a total of an estimated 120 subjects. If approved by the FDA, this protocol will establish the data foundation for a large scale, mass vaccination protocol under an EUA.
hmmm.
That is old news, they filed in Oct, Name Change, More filings on the way the other DD is about their current chances and personnel keeps me hanging around. ya think.
There is nothing wrong with someone accumulating and someone selling when this adds to their Margin Portfolio. The Bid at .0049 was a perfect example. There are other securities out there.
BTW it could have been me trading the shares I picked up the other day at .004. Some food for thought.
Quantum Materials Announces QDX™ HealthID to Support Back-to-Work "Immunization Passport" Programs
Cloud-delivered service leverages modern distributed ledger technologies
to ensure the authenticity and privacy of participants and test kits for disease testing
San Marcos, TX, April 13, 2020 (GLOBE NEWSWIRE) -- Leading American nanomaterial and cadmium-free quantum dot producer and product company Quantum Materials Corp (OTCQB: QTMM) today announced QDX™ HealthID, a blockchain-based service that provides end-to-end visibility to support testing and immunization for infectious diseases on a global scale.
During the past year, QMC developed a secure authenticity platform leveraging nanoparticles as a track/trace mechanism to verify the origin of products in order to mitigate counterfeiting. As the COVID-19 pandemic unfolded, a related near-term use case of validating the health status of coronavirus patients presented itself. Based on QMC’s authenticity technology, QDXTM HealthID addresses this use case, and further leverages cloud and mobile technology to deliver a service that is inexpensive to implement and easy to use for both patients and medical professionals.
The QDXTM HealthID service features an open and extensible architecture that is capable of monitoring and tracing outbreaks of other diseases, including epidemics and pandemics. In particular, it supports multiple methods of authenticating the individuals being tested, those that are administering the test, and the test kits themselves, whether they be to detect the presence of the virus itself or associated antibodies.
Most importantly, QDXTM HealthID facilitates the ability of federal, state, county and local governments to not only coordinate treatment programs but also enable individuals who are eligible to rejoin the workforce to do so more quickly. In addition, the service provides a valuable channel for communicating with individuals, offering them the ability to schedule a test at the nearest available testing center and providing them with all test results.
More specifically, governments and health agencies must operate with the highest levels of confidence in the authenticity of all aspects of medical testing in order to coordinate effective treatment responses. Moreover, verification of an individual's health and immunization status is paramount when considering whether that person should be cleared to re-enter the workforce. The QDX™ HealthID service provides custom workflows that guide an individual through a HIPAA-compliant process that allow for an expedited return to work.
"QDXTM HealthID supports vital population health and economic rebuilding imperatives," says Stephen B. Squires, President & CEO of QMC. "Not only does this service facilitate improved health outcomes for patients, but it also underpins back-to-work certifications, sometimes referred to as immunization passports." Additionally, Les Paull, Phd., CEO of QMVT LLC, which is responsible for sales and marketing of QMC’s innovations, states “The world must have a system that eliminates the fears and anxiety of not knowing who is able to return to work."
For individuals, the QDX™ HealthID immunization passport runs as a secure mobile app that provides an intuitive and user-friendly interface that can be understood by all. It features a color-coded (green; yellow; red) indicator that can be readily shared and authenticated by others using a QR code. When green, it is proof of an individual’s clearance to interact in social and work environments.
In compliance with appropriate data privacy regulations, such as HIPAA, QDX™ HealthID provides on-demand test result data to an individual taking a test and the person administering the test. QMC stands ready to work hand in hand with federal and state health agencies, such as the Centers for Disease Control, the National Institutes of Health and State Offices of Public Health, to provide de-identified datasets to monitor and study population health.
Available globally via Microsoft’s Azure cloud, QDX™ HealthID implements open APIs and data standards, including FHIR/HL-7, for ready integration with existing EMR and analytics systems and distributed ledger applications via the Digital Asset Modeling Language (DAML).
http://www.globenewswire.com/news-release/2020/04/13/2015078/0/en/Quantum-Materials-Announces-QDX-HealthID-to-Support-Back-to-Work-Immunization-Passport-Programs.html
Positive are we. I see cheap shares upcoming just in case.
Delays happen in the Covid-19 World.
GBBC member Blockchain Technology Partners & Quantum Materials Corp present on securing supply chains using blockchain, cloud, and nanotech
About this Event
Submit questions in advance: media@gbbcouncil.org
The Global Business Blockchain Council (GBBC) has launched the GBBC Virtual Members Forum to highlight the work of leading companies in the blockchain space through open town halls and presentations hosted every other Thursday from 9:15am-10:00am EDT.
On April 16th, Duncan Johnston-Watt, CEO of Blockchain Technology Partners (BTP) will present alongside Jay Williams, Chief Technology Officer of Quantum Materials Corp., on their project to secure supply chains using a combination of blockchain, cloud, and nanotechnology.
Together, BTP and QMC have developed a production-ready blockchain platform to tackle counterfeiting in high-value supply chains by tracking nanoscale optical signatures, which are embedded into materials during the production process. The blockchain, cloud, and nanotechnology-based solution makes extensive use of DAML, GBBC member Digital Asset's smart contract programming language, Hyperledger Sawtooth, and BTP's blockchain management platform, Sextant.
https://www.eventbrite.com/e/gbbc-virtual-forum-blockchain-technology-partners-on-secure-supply-chains-tickets-102299789424
Fresher minds believe India is progressing.
The letter states things are moving along we have a worldwide pandemic. Have a nice evening.
Receiving an e-mail from India is most valid vs here say from uninformed and unproven sources. Have a great evening.
Thanks for the update DX
Holding and Adding if Asks are 4 or under.
Hi Denise
the quota and the point is across.
I have met some great people here
Here for Quantum Materials, I have met some great people here that is up and beyond the shareprice.
They score with a Display maker. ch ching
TCL hmmm. Lets get some rumors started. why not, QMC aint dead yet. lol.
Things are on hold not dead. Welcome back.